Orthotopic Liver Transplantation in Human-Immunodeficiency-Virus-Positive Patients in Germany
Table 1
Demographic data and clinical characteristics of all 32 HIV-positive patients who received a liver graft between July 1997 and July 2011 in Germany.
Age (median (IQR))
47 37–52
Gender (male/female)
31: 01
Risk of HIV infection ((%))(a)
Blood products
13/30 (43%)
Homo/heterosexual
9/30 (30%)
Intravenous drug abuse
6/30 (20%)
Unknown
2/30 (7%)
CD4 count (Cell/L) (median (IQR))(a)
266/L 197–370
CD4 count >200 ( (%))
22/31 (71%)
CD4 count >100 ( (%))
7/31 (23%)
CD4 count <100 ( (%))
2/31 (6%)
Plasma HIV RNA (<50 copies/mL) ( (%))(a)
16/31 (52%)
Antiretroviral therapy before OLT ( (%))(a)
PI-based regimen
17/31 (55%)
Efavirenz-based regimen
6/31 (19%)
Efavirenz and Kaletra
1/31 (3%)
3 NRTI
4/31 (13%)
No ART
3/31 (10%)
Antiretroviral therapy after OLT ( (%))(a)
PI-based regimen
17/30 (57%)
Efavirenz-based regimen
3/30 (10%)
Efavirenz and Kaletra
1/30 (3%)
3 NRTI
6/30 (20%)
No ART
3/30 (10%)
Reasons for OLT
HCV coinfection
19 (1 ETOH, 5 HCC)
HCV+HBV coinfection
1 (1 HCC)
HBV coinfection
10 (1 ETOH, 1 HCC)
HBV+HCV+HDV coinfection
1
Budd-Chiari syndrome
1
Child-Pugh score and Meld score at the day of OLT(a)
Child-Pugh class A ( (%))
5/30 (17%)
Child-Pugh class B ( (%))
7/30 (23%)
Child-Pugh class C ( (%))
18/30 (60%)
Meld (median (IQR))(a)
17 13–29]
Ascites prior to OLT(a)
14/29 (48%)
Hepatic encephalopathy prior to OLT(a)
8/29 (28%)
Variceal hemorrhage prior to OLT(a)
4/29 (14%)
PI: protease inhibitor; NRTI: nucleoside/nucleotide reverse transcriptase inhibitor; ETOH: alcoholic cirrhosis; HCC: hepatocellular carcinoma; HCV: hepatitis C; HBV: hepatitis B; HDV: hepatitis D.
(a)Information was not available for all patients.
